nodes	percent_of_prediction	percent_of_DWPC	metapath
Cysteamine—SST—vertebral column—ankylosing spondylitis	0.0931	1	CbGeAlD
Cysteamine—Pseudotumor—Dexamethasone—ankylosing spondylitis	0.0628	0.0827	CcSEcCtD
Cysteamine—Pseudotumor—Betamethasone—ankylosing spondylitis	0.0628	0.0827	CcSEcCtD
Cysteamine—MPO—IL23-mediated signaling events—IL23R—ankylosing spondylitis	0.0286	0.195	CbGpPWpGaD
Cysteamine—Mass—Dexamethasone—ankylosing spondylitis	0.0261	0.0343	CcSEcCtD
Cysteamine—Mass—Betamethasone—ankylosing spondylitis	0.0261	0.0343	CcSEcCtD
Cysteamine—Gastrointestinal ulcer—Methotrexate—ankylosing spondylitis	0.0178	0.0234	CcSEcCtD
Cysteamine—Benign intracranial hypertension—Prednisolone—ankylosing spondylitis	0.0154	0.0203	CcSEcCtD
Cysteamine—Gastrointestinal ulcer haemorrhage—Methotrexate—ankylosing spondylitis	0.0144	0.0189	CcSEcCtD
Cysteamine—Papilloedema—Prednisolone—ankylosing spondylitis	0.0143	0.0188	CcSEcCtD
Cysteamine—Skin striae—Prednisolone—ankylosing spondylitis	0.0143	0.0188	CcSEcCtD
Cysteamine—Benign intracranial hypertension—Triamcinolone—ankylosing spondylitis	0.0142	0.0187	CcSEcCtD
Cysteamine—Benign intracranial hypertension—Methylprednisolone—ankylosing spondylitis	0.0142	0.0186	CcSEcCtD
Cysteamine—Papilloedema—Triamcinolone—ankylosing spondylitis	0.0131	0.0173	CcSEcCtD
Cysteamine—Skin striae—Triamcinolone—ankylosing spondylitis	0.0131	0.0173	CcSEcCtD
Cysteamine—Papilloedema—Methylprednisolone—ankylosing spondylitis	0.0131	0.0172	CcSEcCtD
Cysteamine—Skin striae—Methylprednisolone—ankylosing spondylitis	0.0131	0.0172	CcSEcCtD
Cysteamine—Benign intracranial hypertension—Betamethasone—ankylosing spondylitis	0.0129	0.0169	CcSEcCtD
Cysteamine—Benign intracranial hypertension—Dexamethasone—ankylosing spondylitis	0.0129	0.0169	CcSEcCtD
Cysteamine—SST—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.0125	0.0849	CbGpPWpGaD
Cysteamine—Skin striae—Betamethasone—ankylosing spondylitis	0.0119	0.0157	CcSEcCtD
Cysteamine—Papilloedema—Dexamethasone—ankylosing spondylitis	0.0119	0.0157	CcSEcCtD
Cysteamine—Papilloedema—Betamethasone—ankylosing spondylitis	0.0119	0.0157	CcSEcCtD
Cysteamine—Skin striae—Dexamethasone—ankylosing spondylitis	0.0119	0.0157	CcSEcCtD
Cysteamine—MPO—IL23-mediated signaling events—IL17A—ankylosing spondylitis	0.0114	0.0776	CbGpPWpGaD
Cysteamine—Benign intracranial hypertension—Prednisone—ankylosing spondylitis	0.0112	0.0148	CcSEcCtD
Cysteamine—MPO—IL23-mediated signaling events—IL12B—ankylosing spondylitis	0.0106	0.0722	CbGpPWpGaD
Cysteamine—Papilloedema—Prednisone—ankylosing spondylitis	0.0104	0.0136	CcSEcCtD
Cysteamine—Skin striae—Prednisone—ankylosing spondylitis	0.0104	0.0136	CcSEcCtD
Cysteamine—SST—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.00859	0.0586	CbGpPWpGaD
Cysteamine—Optic neuritis—Prednisolone—ankylosing spondylitis	0.00738	0.0097	CcSEcCtD
Cysteamine—Optic neuritis—Triamcinolone—ankylosing spondylitis	0.00678	0.00892	CcSEcCtD
Cysteamine—Optic neuritis—Methylprednisolone—ankylosing spondylitis	0.00677	0.0089	CcSEcCtD
Cysteamine—SST—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.00619	0.0422	CbGpPWpGaD
Cysteamine—Optic neuritis—Betamethasone—ankylosing spondylitis	0.00615	0.0081	CcSEcCtD
Cysteamine—Optic neuritis—Dexamethasone—ankylosing spondylitis	0.00615	0.0081	CcSEcCtD
Cysteamine—SST—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.00615	0.0419	CbGpPWpGaD
Cysteamine—NPY2R—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.00589	0.0402	CbGpPWpGaD
Cysteamine—Appetite absent—Methotrexate—ankylosing spondylitis	0.00554	0.00728	CcSEcCtD
Cysteamine—Optic neuritis—Prednisone—ankylosing spondylitis	0.00536	0.00705	CcSEcCtD
Cysteamine—SST—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.00526	0.0359	CbGpPWpGaD
Cysteamine—NPY2R—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.00505	0.0344	CbGpPWpGaD
Cysteamine—MPO—Vitamin B12 Metabolism—CRP—ankylosing spondylitis	0.00504	0.0343	CbGpPWpGaD
Cysteamine—Encephalopathy—Methotrexate—ankylosing spondylitis	0.00429	0.00565	CcSEcCtD
Cysteamine—MPO—Folate Metabolism—CRP—ankylosing spondylitis	0.0041	0.0279	CbGpPWpGaD
Cysteamine—SST—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.00401	0.0273	CbGpPWpGaD
Cysteamine—NPY2R—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.00384	0.0262	CbGpPWpGaD
Cysteamine—Blood alkaline phosphatase increased—Methylprednisolone—ankylosing spondylitis	0.00347	0.00457	CcSEcCtD
Cysteamine—MPO—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.00326	0.0222	CbGpPWpGaD
Cysteamine—Affect lability—Prednisolone—ankylosing spondylitis	0.00324	0.00426	CcSEcCtD
Cysteamine—Mood swings—Prednisolone—ankylosing spondylitis	0.00312	0.0041	CcSEcCtD
Cysteamine—Bone disorder—Methotrexate—ankylosing spondylitis	0.00305	0.00401	CcSEcCtD
Cysteamine—Eye pain—Dexamethasone—ankylosing spondylitis	0.00304	0.004	CcSEcCtD
Cysteamine—Eye pain—Betamethasone—ankylosing spondylitis	0.00304	0.004	CcSEcCtD
Cysteamine—Affect lability—Triamcinolone—ankylosing spondylitis	0.00298	0.00392	CcSEcCtD
Cysteamine—Affect lability—Methylprednisolone—ankylosing spondylitis	0.00297	0.00391	CcSEcCtD
Cysteamine—MPO—IL23-mediated signaling events—TNF—ankylosing spondylitis	0.00295	0.0201	CbGpPWpGaD
Cysteamine—Hyperkinesia—Prednisone—ankylosing spondylitis	0.00288	0.00378	CcSEcCtD
Cysteamine—Mood swings—Triamcinolone—ankylosing spondylitis	0.00287	0.00377	CcSEcCtD
Cysteamine—Mood swings—Methylprednisolone—ankylosing spondylitis	0.00286	0.00377	CcSEcCtD
Cysteamine—Lethargy—Betamethasone—ankylosing spondylitis	0.0028	0.00369	CcSEcCtD
Cysteamine—Lethargy—Dexamethasone—ankylosing spondylitis	0.0028	0.00369	CcSEcCtD
Cysteamine—Affect lability—Betamethasone—ankylosing spondylitis	0.0027	0.00356	CcSEcCtD
Cysteamine—Affect lability—Dexamethasone—ankylosing spondylitis	0.0027	0.00356	CcSEcCtD
Cysteamine—Mood swings—Dexamethasone—ankylosing spondylitis	0.0026	0.00342	CcSEcCtD
Cysteamine—Mood swings—Betamethasone—ankylosing spondylitis	0.0026	0.00342	CcSEcCtD
Cysteamine—Lethargy—Prednisone—ankylosing spondylitis	0.00244	0.00321	CcSEcCtD
Cysteamine—Affect lability—Prednisone—ankylosing spondylitis	0.00236	0.0031	CcSEcCtD
Cysteamine—SST—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	0.00234	0.016	CbGpPWpGaD
Cysteamine—MPO—Vitamin B12 Metabolism—TNF—ankylosing spondylitis	0.00228	0.0155	CbGpPWpGaD
Cysteamine—Mood swings—Prednisone—ankylosing spondylitis	0.00227	0.00298	CcSEcCtD
Cysteamine—SST—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.00227	0.0154	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.00217	0.0148	CbGpPWpGaD
Cysteamine—Hallucination—Methylprednisolone—ankylosing spondylitis	0.00208	0.00274	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.00206	0.014	CbGpPWpGaD
Cysteamine—Connective tissue disorder—Methylprednisolone—ankylosing spondylitis	0.00205	0.0027	CcSEcCtD
Cysteamine—Lethargy—Methotrexate—ankylosing spondylitis	0.00204	0.00268	CcSEcCtD
Cysteamine—Erythema—Prednisolone—ankylosing spondylitis	0.00198	0.00261	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.00197	0.0134	CbGpPWpGaD
Cysteamine—Mood swings—Methotrexate—ankylosing spondylitis	0.00189	0.00249	CcSEcCtD
Cysteamine—Hallucination—Betamethasone—ankylosing spondylitis	0.00189	0.00249	CcSEcCtD
Cysteamine—Hallucination—Dexamethasone—ankylosing spondylitis	0.00189	0.00249	CcSEcCtD
Cysteamine—Immune system disorder—Methylprednisolone—ankylosing spondylitis	0.00189	0.00248	CcSEcCtD
Cysteamine—Ataxia—Methotrexate—ankylosing spondylitis	0.00188	0.00247	CcSEcCtD
Cysteamine—MPO—Folate Metabolism—TNF—ankylosing spondylitis	0.00185	0.0126	CbGpPWpGaD
Cysteamine—Liver function test abnormal—Methotrexate—ankylosing spondylitis	0.00185	0.00243	CcSEcCtD
Cysteamine—Mental disorder—Methylprednisolone—ankylosing spondylitis	0.00183	0.00241	CcSEcCtD
Cysteamine—Erythema—Triamcinolone—ankylosing spondylitis	0.00182	0.0024	CcSEcCtD
Cysteamine—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.00182	0.00239	CcSEcCtD
Cysteamine—Erythema—Methylprednisolone—ankylosing spondylitis	0.00182	0.00239	CcSEcCtD
Cysteamine—Convulsion—Prednisolone—ankylosing spondylitis	0.00172	0.00226	CcSEcCtD
Cysteamine—Hypertension—Prednisolone—ankylosing spondylitis	0.00171	0.00225	CcSEcCtD
Cysteamine—Discomfort—Prednisolone—ankylosing spondylitis	0.00167	0.00219	CcSEcCtD
Cysteamine—Erythema—Dexamethasone—ankylosing spondylitis	0.00165	0.00218	CcSEcCtD
Cysteamine—Erythema—Betamethasone—ankylosing spondylitis	0.00165	0.00218	CcSEcCtD
Cysteamine—Hallucination—Prednisone—ankylosing spondylitis	0.00165	0.00217	CcSEcCtD
Cysteamine—Connective tissue disorder—Prednisone—ankylosing spondylitis	0.00163	0.00214	CcSEcCtD
Cysteamine—Anaphylactic shock—Prednisolone—ankylosing spondylitis	0.00162	0.00213	CcSEcCtD
Cysteamine—Convulsion—Triamcinolone—ankylosing spondylitis	0.00158	0.00208	CcSEcCtD
Cysteamine—Convulsion—Methylprednisolone—ankylosing spondylitis	0.00158	0.00207	CcSEcCtD
Cysteamine—Hypertension—Triamcinolone—ankylosing spondylitis	0.00157	0.00207	CcSEcCtD
Cysteamine—Hypertension—Methylprednisolone—ankylosing spondylitis	0.00157	0.00207	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.00154	0.00202	CcSEcCtD
Cysteamine—Discomfort—Triamcinolone—ankylosing spondylitis	0.00153	0.00202	CcSEcCtD
Cysteamine—Discomfort—Methylprednisolone—ankylosing spondylitis	0.00153	0.00201	CcSEcCtD
Cysteamine—Renal failure—Methotrexate—ankylosing spondylitis	0.00152	0.00199	CcSEcCtD
Cysteamine—Confusional state—Methylprednisolone—ankylosing spondylitis	0.0015	0.00197	CcSEcCtD
Cysteamine—Immune system disorder—Prednisone—ankylosing spondylitis	0.0015	0.00197	CcSEcCtD
Cysteamine—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.00149	0.00196	CcSEcCtD
Cysteamine—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.00149	0.00195	CcSEcCtD
Cysteamine—MPO—Selenium Micronutrient Network—TNF—ankylosing spondylitis	0.00147	0.01	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—MMP3—ankylosing spondylitis	0.00146	0.00998	CbGpPWpGaD
Cysteamine—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.00146	0.00192	CcSEcCtD
Cysteamine—Mental disorder—Prednisone—ankylosing spondylitis	0.00145	0.00191	CcSEcCtD
Cysteamine—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.00144	0.0019	CcSEcCtD
Cysteamine—Erythema—Prednisone—ankylosing spondylitis	0.00144	0.0019	CcSEcCtD
Cysteamine—Malnutrition—Prednisone—ankylosing spondylitis	0.00144	0.0019	CcSEcCtD
Cysteamine—Convulsion—Dexamethasone—ankylosing spondylitis	0.00143	0.00189	CcSEcCtD
Cysteamine—Convulsion—Betamethasone—ankylosing spondylitis	0.00143	0.00189	CcSEcCtD
Cysteamine—Hypertension—Dexamethasone—ankylosing spondylitis	0.00143	0.00188	CcSEcCtD
Cysteamine—Hypertension—Betamethasone—ankylosing spondylitis	0.00143	0.00188	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—MMP3—ankylosing spondylitis	0.0014	0.00957	CbGpPWpGaD
Cysteamine—Discomfort—Dexamethasone—ankylosing spondylitis	0.00139	0.00183	CcSEcCtD
Cysteamine—Discomfort—Betamethasone—ankylosing spondylitis	0.00139	0.00183	CcSEcCtD
Cysteamine—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.00137	0.0018	CcSEcCtD
Cysteamine—Urethral disorder—Methotrexate—ankylosing spondylitis	0.00136	0.00178	CcSEcCtD
Cysteamine—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.00135	0.00178	CcSEcCtD
Cysteamine—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.00135	0.00178	CcSEcCtD
Cysteamine—Feeling abnormal—Prednisolone—ankylosing spondylitis	0.00133	0.00175	CcSEcCtD
Cysteamine—Anaemia—Prednisone—ankylosing spondylitis	0.00133	0.00175	CcSEcCtD
Cysteamine—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.00132	0.00174	CcSEcCtD
Cysteamine—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.00132	0.00174	CcSEcCtD
Cysteamine—Agitation—Prednisone—ankylosing spondylitis	0.00132	0.00174	CcSEcCtD
Cysteamine—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.00131	0.00172	CcSEcCtD
Cysteamine—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.00131	0.00172	CcSEcCtD
Cysteamine—Anorexia—Dexamethasone—ankylosing spondylitis	0.00129	0.00169	CcSEcCtD
Cysteamine—Anorexia—Betamethasone—ankylosing spondylitis	0.00129	0.00169	CcSEcCtD
Cysteamine—Urticaria—Prednisolone—ankylosing spondylitis	0.00129	0.00169	CcSEcCtD
Cysteamine—Fatigue—Triamcinolone—ankylosing spondylitis	0.00128	0.00169	CcSEcCtD
Cysteamine—Fatigue—Methylprednisolone—ankylosing spondylitis	0.00128	0.00168	CcSEcCtD
Cysteamine—Immune system disorder—Methotrexate—ankylosing spondylitis	0.00125	0.00164	CcSEcCtD
Cysteamine—Convulsion—Prednisone—ankylosing spondylitis	0.00125	0.00164	CcSEcCtD
Cysteamine—Hypertension—Prednisone—ankylosing spondylitis	0.00124	0.00164	CcSEcCtD
Cysteamine—Feeling abnormal—Triamcinolone—ankylosing spondylitis	0.00123	0.00161	CcSEcCtD
Cysteamine—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	0.00122	0.00161	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.00122	0.0016	CcSEcCtD
Cysteamine—SST—Signaling Pathways—PTGER4—ankylosing spondylitis	0.00122	0.00828	CbGpPWpGaD
Cysteamine—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.00121	0.0016	CcSEcCtD
Cysteamine—Discomfort—Prednisone—ankylosing spondylitis	0.00121	0.00159	CcSEcCtD
Cysteamine—Mental disorder—Methotrexate—ankylosing spondylitis	0.00121	0.00159	CcSEcCtD
Cysteamine—Erythema—Methotrexate—ankylosing spondylitis	0.0012	0.00158	CcSEcCtD
Cysteamine—Malnutrition—Methotrexate—ankylosing spondylitis	0.0012	0.00158	CcSEcCtD
Cysteamine—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.00119	0.00157	CcSEcCtD
Cysteamine—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.00119	0.00156	CcSEcCtD
Cysteamine—Dyspepsia—Betamethasone—ankylosing spondylitis	0.00119	0.00156	CcSEcCtD
Cysteamine—Urticaria—Triamcinolone—ankylosing spondylitis	0.00118	0.00156	CcSEcCtD
Cysteamine—Urticaria—Methylprednisolone—ankylosing spondylitis	0.00118	0.00155	CcSEcCtD
Cysteamine—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.00118	0.00155	CcSEcCtD
Cysteamine—Anaphylactic shock—Prednisone—ankylosing spondylitis	0.00118	0.00155	CcSEcCtD
Cysteamine—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.00117	0.00154	CcSEcCtD
Cysteamine—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.00117	0.00154	CcSEcCtD
Cysteamine—Decreased appetite—Betamethasone—ankylosing spondylitis	0.00117	0.00154	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.00117	0.00153	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.00117	0.00153	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—PTGER4—ankylosing spondylitis	0.00117	0.00794	CbGpPWpGaD
Cysteamine—Fatigue—Dexamethasone—ankylosing spondylitis	0.00116	0.00153	CcSEcCtD
Cysteamine—Fatigue—Betamethasone—ankylosing spondylitis	0.00116	0.00153	CcSEcCtD
Cysteamine—Nervous system disorder—Prednisone—ankylosing spondylitis	0.00115	0.00152	CcSEcCtD
Cysteamine—Skin disorder—Prednisone—ankylosing spondylitis	0.00114	0.0015	CcSEcCtD
Cysteamine—Anorexia—Prednisone—ankylosing spondylitis	0.00112	0.00147	CcSEcCtD
Cysteamine—Anaemia—Methotrexate—ankylosing spondylitis	0.00111	0.00146	CcSEcCtD
Cysteamine—Feeling abnormal—Dexamethasone—ankylosing spondylitis	0.00111	0.00146	CcSEcCtD
Cysteamine—Feeling abnormal—Betamethasone—ankylosing spondylitis	0.00111	0.00146	CcSEcCtD
Cysteamine—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.0011	0.00145	CcSEcCtD
Cysteamine—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.0011	0.00145	CcSEcCtD
Cysteamine—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.0011	0.00144	CcSEcCtD
Cysteamine—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.00109	0.00144	CcSEcCtD
Cysteamine—Leukopenia—Methotrexate—ankylosing spondylitis	0.00108	0.00142	CcSEcCtD
Cysteamine—Urticaria—Dexamethasone—ankylosing spondylitis	0.00107	0.00141	CcSEcCtD
Cysteamine—Urticaria—Betamethasone—ankylosing spondylitis	0.00107	0.00141	CcSEcCtD
Cysteamine—Dizziness—Prednisolone—ankylosing spondylitis	0.00107	0.00141	CcSEcCtD
Cysteamine—Asthenia—Triamcinolone—ankylosing spondylitis	0.00107	0.0014	CcSEcCtD
Cysteamine—Abdominal pain—Betamethasone—ankylosing spondylitis	0.00107	0.0014	CcSEcCtD
Cysteamine—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.00107	0.0014	CcSEcCtD
Cysteamine—Body temperature increased—Betamethasone—ankylosing spondylitis	0.00107	0.0014	CcSEcCtD
Cysteamine—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.00107	0.0014	CcSEcCtD
Cysteamine—Asthenia—Methylprednisolone—ankylosing spondylitis	0.00107	0.0014	CcSEcCtD
Cysteamine—Convulsion—Methotrexate—ankylosing spondylitis	0.00104	0.00137	CcSEcCtD
Cysteamine—Dyspepsia—Prednisone—ankylosing spondylitis	0.00104	0.00136	CcSEcCtD
Cysteamine—Decreased appetite—Prednisone—ankylosing spondylitis	0.00102	0.00135	CcSEcCtD
Cysteamine—Rash—Prednisolone—ankylosing spondylitis	0.00102	0.00134	CcSEcCtD
Cysteamine—Dermatitis—Prednisolone—ankylosing spondylitis	0.00102	0.00134	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.00102	0.00134	CcSEcCtD
Cysteamine—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.00102	0.00134	CcSEcCtD
Cysteamine—Fatigue—Prednisone—ankylosing spondylitis	0.00101	0.00133	CcSEcCtD
Cysteamine—Headache—Prednisolone—ankylosing spondylitis	0.00101	0.00133	CcSEcCtD
Cysteamine—Discomfort—Methotrexate—ankylosing spondylitis	0.00101	0.00133	CcSEcCtD
Cysteamine—Constipation—Prednisone—ankylosing spondylitis	0.00101	0.00132	CcSEcCtD
Cysteamine—Confusional state—Methotrexate—ankylosing spondylitis	0.000991	0.0013	CcSEcCtD
Cysteamine—Dizziness—Triamcinolone—ankylosing spondylitis	0.000984	0.00129	CcSEcCtD
Cysteamine—Anaphylactic shock—Methotrexate—ankylosing spondylitis	0.000983	0.00129	CcSEcCtD
Cysteamine—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000982	0.00129	CcSEcCtD
Cysteamine—Feeling abnormal—Prednisone—ankylosing spondylitis	0.000969	0.00128	CcSEcCtD
Cysteamine—Asthenia—Dexamethasone—ankylosing spondylitis	0.000969	0.00127	CcSEcCtD
Cysteamine—Asthenia—Betamethasone—ankylosing spondylitis	0.000969	0.00127	CcSEcCtD
Cysteamine—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000964	0.00127	CcSEcCtD
Cysteamine—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000962	0.00127	CcSEcCtD
Cysteamine—Nausea—Prednisolone—ankylosing spondylitis	0.000961	0.00126	CcSEcCtD
Cysteamine—Skin disorder—Methotrexate—ankylosing spondylitis	0.000955	0.00126	CcSEcCtD
Cysteamine—Vomiting—Triamcinolone—ankylosing spondylitis	0.000946	0.00124	CcSEcCtD
Cysteamine—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000944	0.00124	CcSEcCtD
Cysteamine—Rash—Triamcinolone—ankylosing spondylitis	0.000939	0.00123	CcSEcCtD
Cysteamine—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000938	0.00123	CcSEcCtD
Cysteamine—Anorexia—Methotrexate—ankylosing spondylitis	0.000937	0.00123	CcSEcCtD
Cysteamine—Rash—Methylprednisolone—ankylosing spondylitis	0.000936	0.00123	CcSEcCtD
Cysteamine—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000936	0.00123	CcSEcCtD
Cysteamine—Urticaria—Prednisone—ankylosing spondylitis	0.000934	0.00123	CcSEcCtD
Cysteamine—Headache—Triamcinolone—ankylosing spondylitis	0.000932	0.00123	CcSEcCtD
Cysteamine—Headache—Methylprednisolone—ankylosing spondylitis	0.00093	0.00122	CcSEcCtD
Cysteamine—Abdominal pain—Prednisone—ankylosing spondylitis	0.00093	0.00122	CcSEcCtD
Cysteamine—Body temperature increased—Prednisone—ankylosing spondylitis	0.00093	0.00122	CcSEcCtD
Cysteamine—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000924	0.00122	CcSEcCtD
Cysteamine—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000924	0.00122	CcSEcCtD
Cysteamine—Dizziness—Dexamethasone—ankylosing spondylitis	0.000893	0.00117	CcSEcCtD
Cysteamine—Dizziness—Betamethasone—ankylosing spondylitis	0.000893	0.00117	CcSEcCtD
Cysteamine—Nausea—Triamcinolone—ankylosing spondylitis	0.000884	0.00116	CcSEcCtD
Cysteamine—Nausea—Methylprednisolone—ankylosing spondylitis	0.000882	0.00116	CcSEcCtD
Cysteamine—Somnolence—Methotrexate—ankylosing spondylitis	0.000874	0.00115	CcSEcCtD
Cysteamine—Hypersensitivity—Prednisone—ankylosing spondylitis	0.000867	0.00114	CcSEcCtD
Cysteamine—Dyspepsia—Methotrexate—ankylosing spondylitis	0.000865	0.00114	CcSEcCtD
Cysteamine—SST—Signaling Pathways—MMP3—ankylosing spondylitis	0.000865	0.0059	CbGpPWpGaD
Cysteamine—Vomiting—Betamethasone—ankylosing spondylitis	0.000859	0.00113	CcSEcCtD
Cysteamine—Vomiting—Dexamethasone—ankylosing spondylitis	0.000859	0.00113	CcSEcCtD
Cysteamine—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000855	0.00112	CcSEcCtD
Cysteamine—Rash—Dexamethasone—ankylosing spondylitis	0.000852	0.00112	CcSEcCtD
Cysteamine—Rash—Betamethasone—ankylosing spondylitis	0.000852	0.00112	CcSEcCtD
Cysteamine—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000851	0.00112	CcSEcCtD
Cysteamine—Dermatitis—Betamethasone—ankylosing spondylitis	0.000851	0.00112	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000849	0.00112	CcSEcCtD
Cysteamine—Fatigue—Methotrexate—ankylosing spondylitis	0.000847	0.00111	CcSEcCtD
Cysteamine—Headache—Betamethasone—ankylosing spondylitis	0.000846	0.00111	CcSEcCtD
Cysteamine—Headache—Dexamethasone—ankylosing spondylitis	0.000846	0.00111	CcSEcCtD
Cysteamine—Asthenia—Prednisone—ankylosing spondylitis	0.000844	0.00111	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—MMP3—ankylosing spondylitis	0.00083	0.00565	CbGpPWpGaD
Cysteamine—Feeling abnormal—Methotrexate—ankylosing spondylitis	0.00081	0.00107	CcSEcCtD
Cysteamine—Diarrhoea—Prednisone—ankylosing spondylitis	0.000805	0.00106	CcSEcCtD
Cysteamine—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000804	0.00106	CcSEcCtD
Cysteamine—Nausea—Betamethasone—ankylosing spondylitis	0.000802	0.00106	CcSEcCtD
Cysteamine—Nausea—Dexamethasone—ankylosing spondylitis	0.000802	0.00106	CcSEcCtD
Cysteamine—Urticaria—Methotrexate—ankylosing spondylitis	0.000781	0.00103	CcSEcCtD
Cysteamine—Dizziness—Prednisone—ankylosing spondylitis	0.000778	0.00102	CcSEcCtD
Cysteamine—Abdominal pain—Methotrexate—ankylosing spondylitis	0.000777	0.00102	CcSEcCtD
Cysteamine—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000777	0.00102	CcSEcCtD
Cysteamine—Vomiting—Prednisone—ankylosing spondylitis	0.000748	0.000984	CcSEcCtD
Cysteamine—Rash—Prednisone—ankylosing spondylitis	0.000742	0.000976	CcSEcCtD
Cysteamine—Dermatitis—Prednisone—ankylosing spondylitis	0.000741	0.000975	CcSEcCtD
Cysteamine—Headache—Prednisone—ankylosing spondylitis	0.000737	0.000969	CcSEcCtD
Cysteamine—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.000724	0.000953	CcSEcCtD
Cysteamine—Asthenia—Methotrexate—ankylosing spondylitis	0.000705	0.000928	CcSEcCtD
Cysteamine—Nausea—Prednisone—ankylosing spondylitis	0.000699	0.000919	CcSEcCtD
Cysteamine—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000673	0.000885	CcSEcCtD
Cysteamine—Dizziness—Methotrexate—ankylosing spondylitis	0.00065	0.000855	CcSEcCtD
Cysteamine—Vomiting—Methotrexate—ankylosing spondylitis	0.000625	0.000822	CcSEcCtD
Cysteamine—Rash—Methotrexate—ankylosing spondylitis	0.00062	0.000815	CcSEcCtD
Cysteamine—Dermatitis—Methotrexate—ankylosing spondylitis	0.000619	0.000815	CcSEcCtD
Cysteamine—Headache—Methotrexate—ankylosing spondylitis	0.000616	0.00081	CcSEcCtD
Cysteamine—Nausea—Methotrexate—ankylosing spondylitis	0.000584	0.000768	CcSEcCtD
